Catalyst Wire Dossier Catalyst Wire Dossier

Abacavir/dolutegravir/lamivudine

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Abacavir/dolutegravir/lamivudine, covering 2018-07-23 to 2018-07-23. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults [Phase 3]

See pricing